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Bleeding is the most frequent complication related toimplantation of a mechanical cardiac assist device.1Recombinant activated factor VII (NovoSeven; NovoNordisk, Bagsvaerd, Denmark) was developed as a pro-
hemostatic agent. We report the successful use of recombinant
activated factor VII to control bleeding abnormalities in a patient
with a left ventricular assist device (LVAD).
Clinical Summary
After repeated cardiac surgery (mitral and later tricuspid annulo-
plasty, implantation of a mechanical mitral valve, and subsequent
reimplantation of an artificial mitral valve), a 34-year-old male
patient was admitted to the cardiac surgical intensive care unit with
severe left ventricular dysfunction. Hemostatic disturbances were
also observed, with the following initial coagulation parameters:
international normalized ratio (INR) 2.22, antithrombin III
48.84%, platelet count 35 × 109/L, and a negative result of the D-
dimers test (<200 µg/L). 
Cardiac shock developed despite high and increasing doses of
inotropic agents. To unload the failing heart and prevent the
patient’s condition from deteriorating into multiple organ failure,
we implanted a pneumatically driven, diaphragm-type LVAD
(POLVAD, Zabrze, Poland). The device was placed paracorporeal-
ly between the left atrium and ascending aorta. The pump was
operating in an asynchronous mode, and it was giving a pump out-
put of about 5.2 L/min, thereby nearly completely unloading the
failing left ventricle. Cardiopulmonary bypass was not used during
the implantation procedure, intraoperative blood loss equaled 2500
mL, and blood products were transfused accordingly.
During the next 6 hours postoperatively, hourly drainage
exceeded 150 mL. Additionally, the patient had massive epistaxis,
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requiring nasal packing, and excessive oozing from the wound,
which amounted to an extra blood loss of about 800 mL. The
hemostatic disturbances persisted despite the use of conventional
measures. After administration of packed red blood cells, fresh
frozen plasma, platelet concentrate, and tranexamic acid, slight
correction of coagulation parameters was achieved (INR 1.61,
antithrombin III 60.26%, platelet count 89 × 109/L, and fibrinogen
2.71 g/L), yet there was no clinical improvement. 
In an attempt to achieve hemostasis, we administered recombi-
nant activated factor VII (20 µg/kg bolus injection given intra-
venously). Laboratory results after 30 minutes showed an INR of
0.97, and bleeding and oozing significantly decreased (drainage 25
mL/h). Clinical improvement lasted for 2 hours. 
Four hours after the initial dose, the second, higher recombi-
nant activated factor VII dose of 30 µg/kg was administered.
Afterward, laboratory results showed an INR of 0.89. Bleeding and
oozing ceased and hourly drainage decreased below 15 mL. There
were no further episodes of bleeding, and no significant side
effects were observed. Close inspection of the pump chamber per-
formed by a applying light source to the transparent LVAD walls
and cannulas showed neither areas of thrombus formation nor
platelet aggregation. There were no laboratory equivalents of
hypercoagulability, and the D-dimer test results remained negative.
Echocardiography showed no abnormalities of the mechanical
mitral valve. 
The patient survived 7 days with the LVAD. On the second
postimplant day, continuous veno-venous hemoperfusion was
instituted because of oliguric renal failure. In the following days
we observed gradual recovery of kidney and liver function.
However, despite the use of lung-protective ventilatory strategy
(pressure-controlled low tidal volume ventilation), on the seventh
postimplant day a tension pneumothorax developed, precipitating
right ventricular failure. Prompt insertion of a chest tube did not
stop acute circulatory decompensation, and the patient eventually
died. Afterward, the device was removed and examined. It was
found to be free of thrombin and platelet aggregates.
Discussion
Appropriate balancing between the dangers of bleeding and throm-
bosis is a difficult task in the care of the patient with an implanted
mechanical circulatory support device. Risk of bleeding, particu-
larly in the immediate postoperative period, is very high, frequent-
ly necessitating reoperation. On the other hand, because of the sig-
nificant risk of thromboembolic events, introduction of
anticoagulants and antiplatelet agents is indispensable. 
Activated factor VII has the ability to bind to tissue factor
expressed at the site of tissue injury, resulting in site-specific throm-
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bin generation. Formation of tissue factor–activated factor VII
complex not only initiates coagulation cascade, but also provides
the first thrombin molecules necessary for platelet activation.2
Activated recombinant factor VII was previously applied in
patients with hemostatic disorders, for example, hemophilia and
inhibitors to factors VIII or IX.3 Recently, it has been increasingly
used to secure hemostasis in difficult clinical situations.4 Infusion
of recombinant activated factor VII results in an immediate, short-
term, local generation of thrombin at sites of tissue factor expo-
sure, such as surgical wounds. Recombinant activated factor VII
was already safely used to control refractory bleeding in patients
undergoing heart valve replacement surgery.5 Lack of thrombotic
complications after administration of activated recombinant factor
VII in the presence of an artificial device is thus probably related
to its site-specific mode of action.
To our knowledge, this was the first case in which activated
recombinant factor VII was administered in a patient with an
LVAD. Our observation suggests that activated recombinant factor
VII may be safely used to control refractory bleeding in patients
with mechanical cardiac support, but further studies are required.
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